Kyle T. Gustafson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kyle T. Gustafson has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Augusta Modestino
Cancer Early Detection Advanced Research Center Knight Cancer Institute Oregon Health and Science University Portland Oregon USA
4 shared publications- Stuart D. Ibsen
Cancer Early Detection Advanced Research Center Knight Cancer Institute Oregon Health and Science University Portland Oregon USA
4 shared publications Austin Gower
Cancer Early Detection Advanced Research Center, Knight Cancer Institute Oregon Health & Science University Portland Oregon USA
3 shared publications- Jared Michael Fischer
CEDAR Knight Cancer Institute School of Medicine Oregon Health and Science University Portland Oregon 97201 USA
3 shared publications - Anna Malakian
Cancer Early Detection Advanced Research Center Knight Cancer Institute Oregon Health and Science University Portland Oregon USA
2 shared publications - Austin Gower
Cancer Early Detection Advanced Research (CEDAR) Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications
Latest Publications
- Open Access
Liquid Biopsy Differentiation of Pancreatic Cancer From Non‐Cancerous Pancreatic Disease Using Dielectrophoresis‐Recovered Nanoparticles Carrying Cell‐Free DNA and Protein Biomarkers
Cancer‐derived extracellular vesicle (EV) nanoparticles carry important biomarkers but are difficult to recover from plasma, making EV‐based diagnostics a challenge for clinical settings. Here, we demonstrate nanoparticle‐based detection of pancreatic cancer using dielectrophoresis (DEP) nanoparticle recovery technology, which purifies nanoparticles from undiluted plasma and quantifies associated biomarkers. We combined both nanoparticle recovery and biomarker quantification on a single device by simultaneously collecting cell‐free DNA nanoparticles and EVs followed by on‐chip biomarker fluorescent staining for DNA and Glypican‐1. Using a blinded cohort, these biomarkers differentiated pancreatic cancer from benign pancreatic diseases, including cysts, pancreatitis, and precancerous low‐grade intraductal papillary mucinous neoplasm (IPMN) lesions, with a sensitivity of 0.92, a specificity of 0.83, and an AUC of 0.93. The AUC increased to 0.97 for patients over 50 years old. This is higher than the standard invasive endoscopic ultrasound‐guided fine needle aspiration tissue biopsy procedure (AUC 0.79). This study is among the first demonstrating a combined threshold of DNA and protein levels that can distinguish pancreatic cancer from its precursor IPMN lesions. We also demonstrated the detection of early‐stage pancreatic cancer and high‐grade in situ precancerous lesions. This DEP‐based technique shows that multiple types of cancer‐derived nanoparticles can be quickly and easily recovered from plasma making it promising for future clinical diagnostics.
Open AccessLiquid Biopsy Differentiation of Pancreatic Cancer From Non‐Cancerous Pancreatic Disease Using Dielectrophoresis‐Recovered Nanoparticles Carrying Cell‐Free DNA and Protein Biomarkers
Cancer‐derived extracellular vesicle (EV) nanoparticles carry important biomarkers but are difficult to recover from plasma, making EV‐based diagnostics a challenge for clinical settings. Here, we demonstrate nanoparticle‐based detection of pancreatic cancer using dielectrophoresis (DEP) nanoparticle recovery technology, which purifies nanoparticles from undiluted plasma and quantifies associated biomarkers. We combined both nanoparticle recovery and biomarker quantification on a single device by simultaneously collecting cell‐free DNA nanoparticles and EVs followed by on‐chip biomarker fluorescent staining for DNA and Glypican‐1. Using a blinded cohort, these biomarkers differentiated pancreatic cancer from benign pancreatic diseases, including cysts, pancreatitis, and precancerous low‐grade intraductal papillary mucinous neoplasm (IPMN) lesions, with a sensitivity of 0.92, a specificity of 0.83, and an AUC of 0.93. The AUC increased to 0.97 for patients over 50 years old. This is higher than the standard invasive endoscopic ultrasound‐guided fine needle aspiration tissue biopsy procedure (AUC 0.79). This study is among the first demonstrating a combined threshold of DNA and protein levels that can distinguish pancreatic cancer from its precursor IPMN lesions. We also demonstrated the detection of early‐stage pancreatic cancer and high‐grade in situ precancerous lesions. This DEP‐based technique shows that multiple types of cancer‐derived nanoparticles can be quickly and easily recovered from plasma making it promising for future clinical diagnostics.
- Open Access
- 25 July 2024
- Published by Wiley in Electrophoresis
- Vol. 45 (19-20) , 1715-1720
Oligo cyc‐DEP: On‐chip cyclic immunofluorescence profiling of cell‐derived nanoparticles
We present a follow‐on technique for the cyclic‐immunofluorescence profiling of suspension particles isolated using dielectrophoresis. The original lab‐on‐chip technique (“cyc‐DEP” [cyclic immunofluorescent imaging on dielectrophoretic chip]) was designed for the multiplex surveillance of circulating biomarkers. Nanoparticles were collected from low‐volume liquid biopsies using microfluidic dielectrophoretic chip technology. Subsequent rounds of cyclic immunofluorescent labeling and quenching were imaged and quantified with a custom algorithm to detect multiple proteins. While cyc‐DEP improved assay multiplicity, long runtimes threatened its clinical adoption. Here, we modify the original cyc‐DEP platform to reduce assay runtimes. Nanoparticles were formulated from human prostate adenocarcinoma cells and collected using dielectrophoresis. Three proteins were labeled on‐chip with a mixture of short oligonucleotide‐conjugated antibodies. The sample was then incubated with complementary fluorophore‐conjugated oligonucleotides, which were dehybridized using an ethylene carbonate buffer after each round of imaging. Oligonucleotide removal exhibited an average quenching efficiency of 98 ± 3% (n = 12 quenching events), matching the original cyc‐DEP platform. The presented “oligo cyc‐DEP” platform achieved clinically relevant sample‐to‐answer times, reducing the duration for three rounds of cyclic immunolabeling from approximately 20 to 6.5 h—a 67% decrease attributed to rapid fluorophore removal and the consolidated co‐incubation of antibodies.
- 25 July 2024
- Published by Wiley in Electrophoresis
- Vol. 45 (19-20) , 1715-1720
Open AccessOligo cyc‐DEP: On‐chip cyclic immunofluorescence profiling of cell‐derived nanoparticles
We present a follow‐on technique for the cyclic‐immunofluorescence profiling of suspension particles isolated using dielectrophoresis. The original lab‐on‐chip technique (“cyc‐DEP” [cyclic immunofluorescent imaging on dielectrophoretic chip]) was designed for the multiplex surveillance of circulating biomarkers. Nanoparticles were collected from low‐volume liquid biopsies using microfluidic dielectrophoretic chip technology. Subsequent rounds of cyclic immunofluorescent labeling and quenching were imaged and quantified with a custom algorithm to detect multiple proteins. While cyc‐DEP improved assay multiplicity, long runtimes threatened its clinical adoption. Here, we modify the original cyc‐DEP platform to reduce assay runtimes. Nanoparticles were formulated from human prostate adenocarcinoma cells and collected using dielectrophoresis. Three proteins were labeled on‐chip with a mixture of short oligonucleotide‐conjugated antibodies. The sample was then incubated with complementary fluorophore‐conjugated oligonucleotides, which were dehybridized using an ethylene carbonate buffer after each round of imaging. Oligonucleotide removal exhibited an average quenching efficiency of 98 ± 3% (n = 12 quenching events), matching the original cyc‐DEP platform. The presented “oligo cyc‐DEP” platform achieved clinically relevant sample‐to‐answer times, reducing the duration for three rounds of cyclic immunolabeling from approximately 20 to 6.5 h—a 67% decrease attributed to rapid fluorophore removal and the consolidated co‐incubation of antibodies.
- Open Access
- 10 July 2023
- Published by Wiley in Electrophoresis
- Vol. 44 (15-16) , 1234-1246
Enhancement of dielectrophoresis‐based particle collection from high conducting fluids due to partial electrode insulation
Dielectrophoresis (DEP) is a successful method to recover nanoparticles from different types of fluid. The DEP force acting on these particles is created by an electrode microarray that produces a nonuniform electric field. To apply DEP to a highly conducting biological fluid, a protective hydrogel coating over the metal electrodes is required to create a barrier between the electrode and the fluid. This protects the electrodes, reduces the electrolysis of water, and allows the electric field to penetrate into the fluid sample. We observed that the protective hydrogel layer can separate from the electrode and form a closed domed structure and that collection of 100 nm polystyrene beads increased when this occurred. To better understand this collection increase, we used COMSOL Multiphysics software to model the electric field in the presence of the dome filled with different materials ranging from low-conducting gas to high conducting phosphate-buffered saline fluids. The results suggest that as the electrical conductivity of the material inside the dome is reduced, the whole dome acts as an insulator which increases electric field intensity at the electrode edge. This increased intensity widens the high-intensity electric field factor zone resulting in increased collection. This informs how dome formation results in increased particle collection and provides insight into how the electric field can be intensified to the increase collection of particles. These results have important applications for increasing the recovery of biologically-derived nanoparticles from undiluted physiological fluids that have high conductance, including the collection of cancer-derived extracellular vesicles from plasma for liquid biopsy applications.
- 10 July 2023
- Published by Wiley in Electrophoresis
- Vol. 44 (15-16) , 1234-1246
Open AccessEnhancement of dielectrophoresis‐based particle collection from high conducting fluids due to partial electrode insulation
Dielectrophoresis (DEP) is a successful method to recover nanoparticles from different types of fluid. The DEP force acting on these particles is created by an electrode microarray that produces a nonuniform electric field. To apply DEP to a highly conducting biological fluid, a protective hydrogel coating over the metal electrodes is required to create a barrier between the electrode and the fluid. This protects the electrodes, reduces the electrolysis of water, and allows the electric field to penetrate into the fluid sample. We observed that the protective hydrogel layer can separate from the electrode and form a closed domed structure and that collection of 100 nm polystyrene beads increased when this occurred. To better understand this collection increase, we used COMSOL Multiphysics software to model the electric field in the presence of the dome filled with different materials ranging from low-conducting gas to high conducting phosphate-buffered saline fluids. The results suggest that as the electrical conductivity of the material inside the dome is reduced, the whole dome acts as an insulator which increases electric field intensity at the electrode edge. This increased intensity widens the high-intensity electric field factor zone resulting in increased collection. This informs how dome formation results in increased particle collection and provides insight into how the electric field can be intensified to the increase collection of particles. These results have important applications for increasing the recovery of biologically-derived nanoparticles from undiluted physiological fluids that have high conductance, including the collection of cancer-derived extracellular vesicles from plasma for liquid biopsy applications.
- Open Access
- 31 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 143
Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics
Some cancer cells rely heavily on non-essential biomolecules for survival, growth, and proliferation. Enzyme based therapeutics can eliminate these biomolecules, thus specifically targeting neoplastic cells; however, enzyme therapeutics are susceptible to immune clearance, exhibit short half-lives, and require frequent administration. Encapsulation of therapeutic cargo within biocompatible and biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) is a strategy for controlled release. Unfortunately, PLGA NPs exhibit burst release of cargo shortly after delivery or upon introduction to aqueous environments where they decompose via hydrolysis. Here, we show the generation of hybrid silica-coated PLGA (SiLGA) NPs as viable drug delivery vehicles exhibiting sub-200 nm diameters, a metastable Zeta potential, and high loading efficiency and content. Compared to uncoated PLGA NPs, SiLGA NPs offer greater retention of enzymatic activity and slow the burst release of cargo. Thus, SiLGA encapsulation of therapeutic enzymes, such as asparaginase, could reduce frequency of administration, increase half-life, and improve efficacy for patients with a range of diseases.
- 31 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 143
Open AccessHybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics
Some cancer cells rely heavily on non-essential biomolecules for survival, growth, and proliferation. Enzyme based therapeutics can eliminate these biomolecules, thus specifically targeting neoplastic cells; however, enzyme therapeutics are susceptible to immune clearance, exhibit short half-lives, and require frequent administration. Encapsulation of therapeutic cargo within biocompatible and biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) is a strategy for controlled release. Unfortunately, PLGA NPs exhibit burst release of cargo shortly after delivery or upon introduction to aqueous environments where they decompose via hydrolysis. Here, we show the generation of hybrid silica-coated PLGA (SiLGA) NPs as viable drug delivery vehicles exhibiting sub-200 nm diameters, a metastable Zeta potential, and high loading efficiency and content. Compared to uncoated PLGA NPs, SiLGA NPs offer greater retention of enzymatic activity and slow the burst release of cargo. Thus, SiLGA encapsulation of therapeutic enzymes, such as asparaginase, could reduce frequency of administration, increase half-life, and improve efficacy for patients with a range of diseases.
- Open Access
- 1 December 2022
- Published by MDPI AG in Preprints.org
Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics
Some cancer cells rely heavily on non-essential biomolecules for survival, growth, and proliferation. Enzyme based therapeutics can eliminate these biomolecules, thus specifically targeting neoplastic cells; however, enzyme therapeutics are susceptible to immune clearance, exhibit short half-lives, and require frequent administration. Encapsulation of therapeutic cargo within biocompatible and biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) is a strategy for controlled release. Unfortunately, PLGA NPs exhibit burst release of cargo shortly after delivery or upon introduction to aqueous environments where they decompose via hydrolysis. Here we show the generation of hybrid silica-coated PLGA (SiLGA) NPs as viable drug delivery vehicles exhibiting sub-200 nm diameters, a metastable Zeta potential, and high loading efficiency and content. Compared to uncoated PLGA NPs, SiLGA NPs offer greater retention of enzymatic activity and slow the burst release of cargo. Thus, SiLGA encapsulation of therapeutic enzymes, such as asparaginase, could reduce frequency of administration, increase half-life, and improve efficacy for patients with a range of diseases.
- 1 December 2022
- Published by MDPI AG in Preprints.org
Open AccessHybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics
Some cancer cells rely heavily on non-essential biomolecules for survival, growth, and proliferation. Enzyme based therapeutics can eliminate these biomolecules, thus specifically targeting neoplastic cells; however, enzyme therapeutics are susceptible to immune clearance, exhibit short half-lives, and require frequent administration. Encapsulation of therapeutic cargo within biocompatible and biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) is a strategy for controlled release. Unfortunately, PLGA NPs exhibit burst release of cargo shortly after delivery or upon introduction to aqueous environments where they decompose via hydrolysis. Here we show the generation of hybrid silica-coated PLGA (SiLGA) NPs as viable drug delivery vehicles exhibiting sub-200 nm diameters, a metastable Zeta potential, and high loading efficiency and content. Compared to uncoated PLGA NPs, SiLGA NPs offer greater retention of enzymatic activity and slow the burst release of cargo. Thus, SiLGA encapsulation of therapeutic enzymes, such as asparaginase, could reduce frequency of administration, increase half-life, and improve efficacy for patients with a range of diseases.
- Open Access
- 11 July 2022
- Published by Wiley in Electrophoresis
- Vol. 43 (16-17) , 1784-1798
cyc‐DEP: Cyclic immunofluorescence profiling of particles collected using dielectrophoresis
Cancer is a highly heterogenous disease that requires precise detection tools and active surveillance methods. Liquid biopsy assays provide an agnostic way to follow the complex trajectory of cancer, providing better patient stratification tools for optimized treatment. Here, we present the development of a low‐volume liquid biopsy assay called cyc‐DEP (cyclic immunofluorescent imaging on dielectrophoretic chip) to profile biomarkers collected on a dielectrophoretic microfluidic chip platform. To enable on‐chip cyclic imaging, we optimized a fluorophore quenching method and sequential rounds of on‐chip staining with fluorescently conjugated primary antibodies. cyc‐DEP allows for the quantification of a multiplex array of proteins using 25 µl of a patient plasma sample. We utilized nanoparticles from a prostate adenocarcinoma (LNCaP) cell line and a panel of six target proteins to develop our proof‐of‐concept technique. We then used cyc‐DEP to quantify blood plasma levels of target proteins from healthy individuals, low‐grade and high‐grade prostate cancer patients (n = 3 each) in order to demonstrate that our platform is suitable for liquid biopsy analysis in its present form. To ensure accurate quantification of signal intensities and comparisons between different samples, we incorporated a signal intensity normalization method (fluorescent beads) and a custom signal intensity quantification algorithm that account for the distribution of signal across hundreds of collection regions on each chip. Our technique enabled a threefold improvement in multiplicity for detecting proteins associated with fluid samples, opening doors for early detection, and active surveillance through quantification of a multiplex array of biomarkers from low‐volume liquid biopsies.
- 11 July 2022
- Published by Wiley in Electrophoresis
- Vol. 43 (16-17) , 1784-1798
Open Accesscyc‐DEP: Cyclic immunofluorescence profiling of particles collected using dielectrophoresis
Cancer is a highly heterogenous disease that requires precise detection tools and active surveillance methods. Liquid biopsy assays provide an agnostic way to follow the complex trajectory of cancer, providing better patient stratification tools for optimized treatment. Here, we present the development of a low‐volume liquid biopsy assay called cyc‐DEP (cyclic immunofluorescent imaging on dielectrophoretic chip) to profile biomarkers collected on a dielectrophoretic microfluidic chip platform. To enable on‐chip cyclic imaging, we optimized a fluorophore quenching method and sequential rounds of on‐chip staining with fluorescently conjugated primary antibodies. cyc‐DEP allows for the quantification of a multiplex array of proteins using 25 µl of a patient plasma sample. We utilized nanoparticles from a prostate adenocarcinoma (LNCaP) cell line and a panel of six target proteins to develop our proof‐of‐concept technique. We then used cyc‐DEP to quantify blood plasma levels of target proteins from healthy individuals, low‐grade and high‐grade prostate cancer patients (n = 3 each) in order to demonstrate that our platform is suitable for liquid biopsy analysis in its present form. To ensure accurate quantification of signal intensities and comparisons between different samples, we incorporated a signal intensity normalization method (fluorescent beads) and a custom signal intensity quantification algorithm that account for the distribution of signal across hundreds of collection regions on each chip. Our technique enabled a threefold improvement in multiplicity for detecting proteins associated with fluid samples, opening doors for early detection, and active surveillance through quantification of a multiplex array of biomarkers from low‐volume liquid biopsies.
- Open Access
- 24 March 2021
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 21 (7) , 1318-1332
Automated fluorescence quantification of extracellular vesicles collected from blood plasma using dielectrophoresis
Tumor-secreted exosomes and other extracellular vesicles (EVs) in circulation contain valuable biomarkers for early cancer detection and screening. We have previously demonstrated collection of cancer-derived nanoparticles (NPs) directly from whole blood and plasma with a chip-based technique that uses a microelectrode array to generate dielectrophoretic (DEP) forces. This technique enables direct recovery of NPs from whole blood and plasma. The biomarker payloads associated with collected particles can be detected and quantified with immunostaining. Accurately separating the fluorescence intensity of stained biomarkers from background (BG) levels becomes a challenge when analyzing the blood from early-stage cancer patients in which biomarker concentrations are low. To address this challenge, we developed two complementary techniques to standardize the quantification of fluorescently immunolabeled biomarkers collected and concentrated at predictable locations within microfluidic chips. The first technique was an automated algorithm for the quantitative analysis of fluorescence intensity at collection regions within the chip compared to levels at adjacent regions. The algorithm used predictable locations of particle collection within the chip geometry to differentiate regions of collection and BG. We successfully automated the identification and removal of optical artifacts from quantitative calculations. We demonstrated that the automated system performs nearly the same as a human user following a standard protocol for manual artifact removal with Pearson's r-values of 0.999 and 0.998 for two different biomarkers (n = 36 patients). We defined a usable dynamic range of fluorescence intensities corresponding to 1 to 2000 arbitrary units (a.u.). Fluorescence intensities within the dynamic range increased linearly with respect to exposure time and particle concentration. The second technique was the implementation of an internal standard to adjust levels of biomarker fluorescence based on the relative collection efficiency of the chip. Use of the internal standard reduced variability in measured biomarker levels due to differences in chip-to-chip collection efficiency, especially at low biomarker concentrations. The internal standard did not affect linear trends between fluorescence intensity and exposure time. Adjustments using the internal standard improved linear trends between fluorescence intensity and particle concentration. The optical quantification techniques described in this paper can be easily adapted for other lab-on-a-chip platforms that have predefined regions of biomarker or particle collection and that rely on fluorescence detection.
- 24 March 2021
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 21 (7) , 1318-1332
Open AccessAutomated fluorescence quantification of extracellular vesicles collected from blood plasma using dielectrophoresis
Tumor-secreted exosomes and other extracellular vesicles (EVs) in circulation contain valuable biomarkers for early cancer detection and screening. We have previously demonstrated collection of cancer-derived nanoparticles (NPs) directly from whole blood and plasma with a chip-based technique that uses a microelectrode array to generate dielectrophoretic (DEP) forces. This technique enables direct recovery of NPs from whole blood and plasma. The biomarker payloads associated with collected particles can be detected and quantified with immunostaining. Accurately separating the fluorescence intensity of stained biomarkers from background (BG) levels becomes a challenge when analyzing the blood from early-stage cancer patients in which biomarker concentrations are low. To address this challenge, we developed two complementary techniques to standardize the quantification of fluorescently immunolabeled biomarkers collected and concentrated at predictable locations within microfluidic chips. The first technique was an automated algorithm for the quantitative analysis of fluorescence intensity at collection regions within the chip compared to levels at adjacent regions. The algorithm used predictable locations of particle collection within the chip geometry to differentiate regions of collection and BG. We successfully automated the identification and removal of optical artifacts from quantitative calculations. We demonstrated that the automated system performs nearly the same as a human user following a standard protocol for manual artifact removal with Pearson's r-values of 0.999 and 0.998 for two different biomarkers (n = 36 patients). We defined a usable dynamic range of fluorescence intensities corresponding to 1 to 2000 arbitrary units (a.u.). Fluorescence intensities within the dynamic range increased linearly with respect to exposure time and particle concentration. The second technique was the implementation of an internal standard to adjust levels of biomarker fluorescence based on the relative collection efficiency of the chip. Use of the internal standard reduced variability in measured biomarker levels due to differences in chip-to-chip collection efficiency, especially at low biomarker concentrations. The internal standard did not affect linear trends between fluorescence intensity and exposure time. Adjustments using the internal standard improved linear trends between fluorescence intensity and particle concentration. The optical quantification techniques described in this paper can be easily adapted for other lab-on-a-chip platforms that have predefined regions of biomarker or particle collection and that rely on fluorescence detection.
- Top Cited PapersOpen Access
- 7 September 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (9) , eaat7828
Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Peripheral blood MФ–cancer cell fusion hybrids identified in cancer patients correlate with disease stage and overall survival.
- 7 September 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (9) , eaat7828
Top Cited PapersOpen AccessCell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Peripheral blood MФ–cancer cell fusion hybrids identified in cancer patients correlate with disease stage and overall survival.